NEW YORK (GenomeWeb News) – This month, proteomics researchers and industry players met with US Food and Drug Administration regulators to discuss the current status of and future outlook for the field's clinical ambitions.

In large part, the challenges facing protein test developers are the same as those facing molecular diagnostics. However, several questions more specific to proteomics efforts emerged from the discussions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.